These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 22699029)

  • 21. Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder.
    Mbaya P; Alam F; Ashim S; Bennett D
    Hum Psychopharmacol; 2007 Apr; 22(3):129-33. PubMed ID: 17397100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder.
    Leuchter AF; Cook IA; Gilmer WS; Marangell LB; Burgoyne KS; Howland RH; Trivedi MH; Zisook S; Jain R; Fava M; Iosifescu D; Greenwald S
    Psychiatry Res; 2009 Sep; 169(2):132-8. PubMed ID: 19709754
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: results from the PREVENT study.
    Thase ME; Gelenberg A; Kornstein SG; Kocsis JH; Trivedi MH; Ninan P; Li T; Pedersen R; Keller M
    J Psychiatr Res; 2011 Mar; 45(3):412-20. PubMed ID: 20801464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Venlafaxine: new preparation. Just another antidepressant.
    Prescrire Int; 1998 Aug; 7(36):112-4. PubMed ID: 10342950
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effective dose of escitalopram in moderate versus severe DSM-IV major depression.
    Bech P; Andersen HF; Wade A
    Pharmacopsychiatry; 2006 Jul; 39(4):128-34. PubMed ID: 16871468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and tolerability of venlafaxine extended release in patients with major depressive disorder.
    Plesnicar BK
    Psychiatr Danub; 2010 Sep; 22(3):413-7. PubMed ID: 20856184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: a randomized open-label study.
    Amsterdam JD; Shults J
    J Clin Psychopharmacol; 2008 Apr; 28(2):171-81. PubMed ID: 18344727
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population.
    Fang Y; Yuan C; Xu Y; Chen J; Wu Z; Cao L; Yi Z; Hong W; Wang Y; Jiang K; Gao K; Cui X; Nierenberg AA;
    J Clin Psychopharmacol; 2010 Aug; 30(4):357-64. PubMed ID: 20571433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relapse prevention and residual symptoms: a closer analysis of placebo-controlled continuation studies with escitalopram in major depressive disorder, generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder.
    Bech P; Lönn SL; Overø KF
    J Clin Psychiatry; 2010 Feb; 71(2):121-9. PubMed ID: 19961809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D.
    Gaynes BN; Dusetzina SB; Ellis AR; Hansen RA; Farley JF; Miller WC; Stürmer T
    J Clin Psychopharmacol; 2012 Feb; 32(1):114-9. PubMed ID: 22198447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study.
    Zisook S; Lesser IM; Lebowitz B; Rush AJ; Kallenberg G; Wisniewski SR; Nierenberg AA; Fava M; Luther JF; Morris DW; Trivedi MH
    J Clin Psychiatry; 2011 Oct; 72(10):1322-32. PubMed ID: 22075098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heart rate variability during antidepressant treatment with venlafaxine and mirtazapine.
    Terhardt J; Lederbogen F; Feuerhack A; Hamann-Weber B; Gilles M; Schilling C; Lecei O; Deuschle M
    Clin Neuropharmacol; 2013; 36(6):198-202. PubMed ID: 24201230
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heart rate variability and treatment outcome in major depression: a pilot study.
    Jain FA; Cook IA; Leuchter AF; Hunter AM; Davydov DM; Ottaviani C; Tartter M; Crump C; Shapiro D
    Int J Psychophysiol; 2014 Aug; 93(2):204-10. PubMed ID: 24769434
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heart rate time irreversibility is impaired in adolescent major depression.
    Tonhajzerova I; Ondrejka I; Chladekova L; Farsky I; Visnovcova Z; Calkovska A; Jurko A; Javorka M
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Oct; 39(1):212-7. PubMed ID: 22771778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Altered cardiorespiratory coupling in young male adults with excessive online gaming.
    Chang JS; Kim EY; Jung D; Jeong SH; Kim Y; Roh MS; Ahn YM; Hahm BJ
    Biol Psychol; 2015 Sep; 110():159-66. PubMed ID: 26253868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anhedonia among patients with Major Depressive Disorder: A comparison between patients on escitalopram and healthy controls.
    Ng CG; Wong SK; Loh HS; Yee A
    Clin Ter; 2014; 165(6):e384-90. PubMed ID: 25524191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mind and heart: heart rate variability in major depressive disorder and coronary heart disease - a review and recommendations.
    Stapelberg NJ; Hamilton-Craig I; Neumann DL; Shum DH; McConnell H
    Aust N Z J Psychiatry; 2012 Oct; 46(10):946-57. PubMed ID: 22528974
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heart rate variability in major depressive disorder and after antidepressant treatment with agomelatine and paroxetine: Findings from the Taiwan Study of Depression and Anxiety (TAISDA).
    Yeh TC; Kao LC; Tzeng NS; Kuo TB; Huang SY; Chang CC; Chang HA
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():60-7. PubMed ID: 26216863
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utility of event-related potentials in predicting antidepressant treatment response: An iSPOT-D report.
    van Dinteren R; Arns M; Kenemans L; Jongsma ML; Kessels RP; Fitzgerald P; Fallahpour K; Debattista C; Gordon E; Williams LM
    Eur Neuropsychopharmacol; 2015 Nov; 25(11):1981-90. PubMed ID: 26282359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.